Skip to content

Welcome to Discover Pharma! Today is : November 7, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical & Regulatory

  • Biotech & Pharma Business,Clinical & Regulatory

    NICE recommends Nucala for uncontrolled COPD with eosinophilic phenotype on NHS

    NICE has issued draft final guidance recommending Nucala as an [...]

    June 6, 2026
  • Clinical & Regulatory,Digital & Data,Therapeutic Areas

    Scotland launches accredited Alzheimer’s biomarker testing service

    Scottish Brain Sciences (SBS) has launched an accredited laboratory service [...]

    June 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Pierre Fabre moves closer to first-line approval for BRAFTOVI in BRAF-mutant metastatic colorectal cancer

    Pierre Fabre Laboratories has received a positive opinion from the [...]

    June 6, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE backs serplulimab for extensive-stage small cell lung cancer

    People with extensive-stage small cell lung cancer in England and [...]

    June 6, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Quotient Sciences begins Phase 1 study of AI-designed drug formulation

    Quotient Sciences has begun a Phase 1 clinical study evaluating [...]

    June 6, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Baptist Health and START expand access to early-phase cancer trials in South Florida

    Patients across South Florida are set to gain greater access [...]

    June 6, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Genomics and sequencing

    Countable Labs raises $26m to expand Countable PCR platform

    Countable Labs has raised $26 million in an oversubscribed financing [...]

    June 6, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Mestag Therapeutics doses first patient in Phase 1 STARLYS solid tumour trial

    Mestag Therapeutics has dosed the first patient in its Phase [...]

    May 28, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Protara reports durable 12-month responses for TARA-002 in Phase 2 bladder cancer trial

    Protara Therapeutics has reported updated 12-month data from its ongoing [...]

    May 19, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    Veristat launches AI biostatistics platform to accelerate clinical trial data readouts

    Veristat has launched an AI-enabled biostatistics platform designed to reduce [...]

    May 15, 2026
Previous232425Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Isomab data support safety of angiogenic approaches in coronary artery disease
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA approves Tivicay PD for children with HIV weighing at least 2kg
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Tezspire meets Phase 3 endpoints in eosinophilic esophagitis
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top